Frontline Education, a leading provider of administration software purpose-built for educators in K-12, today announced that ...

CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

Day One Biopharmaceuticals' Ojemda sees $57.2M in 2024 sales amid biotech pullback. DAWN's stock is near 52-week lows. Read ...

Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes ...

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...

本项研究的意义：在胶质瘤患者中，术后癫痫发作（EPSs）被认为是与手术相关因素而非肿瘤相关机制所诱发的神经障碍。术后癫痫发作更易发生在肿瘤切除率低于 92.24% 的患者身上，这 有助于改善胶质瘤的个体化管理。

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous ...

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced ...